New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
The New NCI Precision Medicine Trials.
ÌÇÐÄ´«Ã½
The New NCI Precision Medicine Trials. Clinical cancer ÌÇÐÄ´«Ã½ : an official journal of the American Association for Cancer Research Harris, L. N., Blanke, C. D., Erba, H. P., Ford, J. M., Gray, R. J., LeBlanc, M. L., Hu-Lieskovan, S., Litzow, M. R., Luger, S. M., Meric-Bernstam, F., O'Dwyer, P. J., Othus, M. K., Politi, K., Shepherd, L. E., Allegra, C. J., Chen, H. X., Ivy, S. P., Korde, L. A., Little, R. F., McShane, L. M., Moscow, J. A., Patton, D. R., Thurin, M., Yee, L. M., Doroshow, J. H. 2023Abstract
Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First generation trials like NCI-MATCH have proven the principle that studying targeted therapies on a large scale is feasible both from the laboratory and clinical perspectives. However, single agent targeted therapies have shown limited ability to control metastatic disease, despite careful matching of drug to target. As such, newer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI has recently embarked on three 2nd generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.
View details for
View details for